Abstract. H 30 N 2 O 5 ) is a newly synthesized flavonoid that has been confirmed to possess an antitumor effect, but the mechanism is unclear. Our present study was performed to identify the anti-angiogenic activity of this novel compound in vitro and in vivo. LYG-202 inhibited vascular endothelial growth factor (VEGF) stimulated migration and tube formation of human umbilical vein endothelial cells and arrested microvessel outgrowth from rat aortic rings in vitro. Meanwhile, LYG-202 suppressed the neovascularization of Chicken Chorioallantoic Membrane in vivo. Mechanistic studies revealed that LYG-202 suppressed the VEGF-induced tyrosine phosphorylation of KDR/Flk-1 (VEGFR-2) as well as its downstream protein kinases activation, by decreasing phosphorylated forms of serine/threonine kinase Akt, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase. LYG-202 exerts anti-angiogenic activity both in vitro and in vivo, and these results suggest that it deserves further investigation as a promising anti-tumor angiogenesis compound.
Introduction
Flavonoids are found in almost every plant, which act as pharmacologically active constituents in many plant medicines. Epidemiological studies have shown that dietary intake of flavonoids is significantly associated with a reduced risk of cancer, inflammation, and heart disease (1). Indeed, many flavonoids exert anti-oxidative, anti-viral, anti-thrombotic, anti-inflammatory, and anti-cardiovascular disease activities (2) . In addition, the flavonoids are typical phenolic compounds and, therefore, act as potent metal chelators and free radical scavengers (3) . Generally, they display a remarkable array of biochemical and pharmacological actions. Especially, there have been many reports about their anti-angiogenic activity in recent years (4) .
Angiogenesis is the process in which the new blood vessels are formed from pre-existing ones (5) . Under physiological conditions, the growth of blood vessels is essential for organ growth and repair, which is fundamental to normal wound healing, reproduction, and embryonic development (6) . This process is tightly regulated to prevent harmful effects on an individual's health. Inversely, under pathological conditions (7), uncontrolled angiogenesis is a major contributor to a number of diseases such as tumor progression, inflammatory disorders, obesity, asthma, diabetes, multiple sclerosis, endometriosis, AIDS, bacterial infections, and autoimmune disease, due to its ability to supply oxygen and nutrients to the pathologic ischemia position. Therefore, modulation of angiogenesis is considered to be a therapeutic strategy of great importance for human health.
Many flavonoids share anti-angiogenic properties on an experimental basis, including chrysin, kaempferol, fisetin, wogonin, luteolin, and so on (4) . These observations suggested that certain flavonoids were able to inhibit several key events of the angiogenic process such as proliferation, migration, and tube formation of 38 Y Chen et al endothelial cells; expression of vascular endothelial growth factor (VEGF); and activation of matrix metalloprotein proteinases (MMPs). Anti-angiogenic property of flavonoids has been observed in the chick embryo chorioallantoic membrane since they strongly inhibited the formation of new blood vessels (8) . Moreover, this effect has also been confirmed by reducing corneal neovascularization induced by proangiogenic factors such as VEGF and fibroblast growth factor (FGF) in rabbits (9) . Although the molecular mechanism of flavonoid anti-angiogenic activity is still indistinct, it appears to be partly due to blocking some growth factor receptor (VEGF and bFGF-receptor, and so on)-mediated responses and related signal pathways transduction by decreasing phosphorylation of some protein kinases such as p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2, and c-Jun N-terminal kinase (JNK) and also PI3-kinase/Akt (8, 10) .
The flavonoids are phenyl substituted chromones (benzopyran derivatives) consisting of a 15-carbon basic skeleton (C6-C3-C6) (Fig. 1A) , composed of a chroman (C6-C3) nucleus (the benzo ring A and the heterocyclic ring C), also shared by the tocopherols, with a phenyl (the aromatic ring B) substitution usually at the 2-position (11) . According to their substituents, they are usually classified as flavanols, anthocyanidins, flavones, flavanones, and chalcones (12) . As a newly synthesized flavonoid, which bears the same three-ring structure of flavone backbone (Fig. 1B) , LYG-202 may have inhibitory activity against angiogenesis.
In the present study, we demonstrated that LYG-202 possessed anti-angiogenic activity both in vitro and in vivo, and we also investigated the underlying molecular mechanism for this activity.
Materials and Methods

Reagents
LYG-202 was obtained from Dr. Zhiyu Li (China Pharmaceutical University, China). It was dissolved at a concentration of 10 mM in 100% DMSO as a stock solution, stored at −20°C, and diluted with medium before each experiment. The final DMSO concentration did not exceed 0.1% throughout the study; in our study, all the control groups were animals given DMSO at 0.1% final concentration. Recombinant human vascular endothelial cell growth factor was purchased from Chemicon International (Temecula, CA, USA). Primary antibodies for p38 (1:400), p-p38 (1:300), Akt (1:400), p-Akt (1:300), p-ERK1/2 (1:300), and β-actin (1:1000) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibody for ERK1/2 (1:500) was from Millipore (Boston, MA, USA). Antibodies for p-VEGFR-2 (1:1000) and VEGFR-2 (1:1000) were from Cell Signaling Technology (Beverly, MA, USA). IRDyeTM 800-conjugated secondary antibodies were obtained from Rockland, Inc. (Philadelphia, PA, USA) and diluted at the ratio of 1:20,000.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord veins by collagenase treatment as described previously (13) . The harvested cells were grown in medium 199 (Gibco, Grand Island, NY, USA) containing endothelial cell growth supplement (ECGS, 30 μg/ml; Sigma, St. Louis, MO, USA), epidermal growth factor (EGF, 10 ng/ml; Sigma), 20% fetal bovine serum (FBS, Gibco), 100 U/ ml penicillin, and 100 μg/ml streptomycin, pH 7.4. The cells were incubated in a humidified atmosphere of 95% air + 5% CO 2 at 37°C. After 3 -5 passages, HUVECs were collected for use in all experiments.
The cells were obtained from consenting donors, as approved by the Research Ethics Board at the Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, with consideration for human ethics.
Endothelial cell migration assay
Chemotactic motility of HUVECs was assayed using a transwell chamber migration system (Millicell; Millipore, Billerica, MA, USA) containing membranes with 8-μm pore size, as described previously (14) . HUVECs were treated with various concentrations of LYG-202 (0.1, 1, and 10 μM) for 60 min. Cells, including the control group and LYG-202-treated groups, were trypsinized and suspended at a final concentration of 5 × 10 5 cells/ml in M199 containing 1% FBS. Then cell OH LYG-202 Exhibits Antiangiogenic Activity suspension was loaded into the 10-mm upper chamber. Fresh M199 medium (1% FBS) containing VEGF (10 ng/ml) was placed in the lower wells. After incubation at 37°C under 95% air + 5% CO 2 for 4 h, the upper surface of the membranes was swabbed to remove nonmigrated cells, and the cells attached onto the lower surface were fixed, stained, and counted microscopically. The migrated cells were quantified by manual counting, and five randomly chosen fields were analyzed for each group.
Tube formation assay
Tube formation assay was performed as described previously (15) . Briefly, a 96-well plate was coated with 80 μl of matrigel (Becton-Dickinson, Bedford, MA, USA), which was allowed to solidify and polymerized at 37°C for 30 min. HUVECs were incubated in medium containing 1% FBS in the absence or presence of LYG-202 (0.1, 1, and 10 μM) for 60 min. These cells were harvested after trypsin treatment and suspended in medium containing 1% FBS before seeding and plating onto matrigel and then VEGF (10 ng/ml) was added. After 8 h, tubular structures were quantified by manual counting of the tube numbers, and five randomly chosen fields were analyzed for each well.
Rat aortic ring assay
Rat aortic ring assay was performed as described previously (16) . The thoracic aorta was dissected from 6-week-old Sprague-Dawley rats and cut into 1-mm-long rings, and then these rings were placed in 24-well plates. The rings were treated as described previously. Clotting media contained M199 + (M199 with 100 U/ml penicillin and 100 µg/ml streptomycin) plus 0.3% fibrinogen and 0.5% ε-amino-n-caproic acid (ACA, Sigma). Growth media consisted of M199 + with 20% FBS and 0.5% ACA. Then the growth media was added to the wells with or without different concentrations of LYG-202 (1, 4, and 16 μM). Plates were then stored in incubator at 37°C and 5% CO 2 . After 7 days, the microvessel growth was quantified by manually counting the number of microvessels from the rat aortic rings, with five rings used as a group.
The use of animals was in accordance with the guidelines established by the National Science Council of Republic China, with adherence to the ethical guidelines for the care and use of animals.
Chicken chorioallantoic membrane (CAM) assay
Anti-angiogenic activity of LYG-202 on CAM was assayed as described previously (17) . Briefly, fertilized chicken eggs were incubated at 37°C for 9 days. After this incubation, a small hole was punched on the broad side of the egg, and a window was carefully created through the egg shell. Sterilized filter paper disks (5 × 5 mm) saturated with vehicle or with LYG-202 (2.4, 12, and 60 ng/egg) were placed on the CAMs. The eggs were then incubated at 37°C for another 2 days. Lastly, an appropriate volume of 10% fat emulsion (Intralipose, 10%) was injected into the embryo chorioallantois to observe the density and length of vessels toward the CAM face, and then the CAMs were photographed. Ten eggs were used per group, and the number of newly formed vessels was counted.
Western blot analysis
HUVECs were pretreated for 60 min with various concentrations of LYG-202 (0.1, 1, and 10 μM) and stimulated for 10 min with 10 ng/ml VEGF (18) . After stimulation, cells were collected; lysed in lysis buffer [50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% (m/v) Nonidet P-40 (NP-40), 0.2 mM Phenylmethanesulfonyl fluoride (PMSF), 0.1 mM NaF and 1.0 mM dithiothreitol (DTT)], and lysates were clarified by centrifugation at 4°C for 15 min at 13,000 × g. The concentration of protein in the supernatants was measured by the BCA (bicinchoninic acid) assay with a Varioskan multimode microplate spectrophotometer (Thermo, Waltham, MA, USA). Then equal amounts of protein (50 μg) were separated by 8% or 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto the PVDF membranes (Millipore). The blots were incubated with specific antibodies against the indicated primary antibodies overnight at 4°C followed by IRDyeTM800-conjugated secondary antibody for 1 h at 37°C. Detection was performed by the Odyssey Infrared Imaging System (LI-COR; Lincoln, NE, USA). All blots were stripped and reprobed with polyclonal anti-β-actin antibody to ascertain equal loading of proteins.
Statistical analyses
All data in the different experimental groups were expressed as the mean ± S.E.M. These data shown in the study were obtained in at least three independent experiments. Data were tested by one-way analysis of variance (ANOVA), followed by the Bonferroni post-test for multiple-group comparisons. A P-value less than 0.05 was considered as statistically significant.
Results
LYG-202 reduces VEGF-stimulated HUVEC migration
Endothelial cells migration is a critical event in angiogenesis, for which VEGF is a potent stimulator (19) . The Transwell Chamber assay was used to examine whether LYG-202 could inhibit VEGF-induced migration. After 40 Y Chen et al stimulating HUVECs with VEGF (10 ng/ml) for 4 h, a large number of cells migrated to the lower side of the membrane in the Transwell Chamber (Fig. 2) . LYG-202 significantly reduced the number of migrated cells in a concentration-dependent manner. LYG-202 decreased the VEGF-induced migration to 24%, 53%, and 92% over the controls at 0.1, 1, and 10 μM, respectively. These results demonstrate that LYG-202 has an ability to repress VEGF-induced migration of HUVECs.
LYG-202 suppresses tube formation of HUVECs
As tube formation represents one of the late stages of angiogenesis, we next evaluated the effects of LYG-202 on tube formation of HUVECs on a matrigel substratum. Stimulation of HUVECs seeded on matrigel by angiogenic factors such as VEGF and bFGF can promote differentiation of the cells to form capillary-like tubes (20) . The results showed that HUVECs formed a mesh of tubes within 8 h in the group induced by VEGF (10 ng/ml) (Fig. 3) . The tube structures were concentrationdependently disrupted when cells were exposed to LYG-202. HUVECs treated with lower concentrations (0.1 and 1 μM) of LYG-202 differentiated into short tubes but were unable to form meshes, whereas those treated with higher concentration of LYG-202 (10 μM) remained dotted on the matrigel. Quantitative analysis revealed that treatment with LYG-202 resulted in 18%, 59%, and 91% inhibition of VEGF-induced tube formation at 0.1, 1, and 10 μM, respectively. These results indicate that LYG-202 has the ability to block VEGF-induced tube formation of HUVECs.
LYG-202 inhibits angiogenesis in vitro
We further evaluated the anti-angiogenic effects of LYG-202 on the aorta sprout outgrowth assay in vitro, which mimics several stages in angiogenesis, including endothelial cell proliferation, migration, and tube formation. We found that new microvessels began to grow when control cultures were incubated for 5 days, which grew earlier than the ones in LYG-202-treated cultures. After being cultivated for 7 days, the control group formed a large number of microvessel structures. Treatment with LYG-202 at 4 μM resulted in a notable suppression of microvessel formation versus the control (Fig. 4) , with the growing sprouts being shorter and fewer. When treated with 16 μM LYG-202, the microvessel sprouting was inhibited almost completely. Compared with the control group, LYG-202 at 1, 4, and 16 μM inhibited microvessel growth by 15%, 47%, and 85%, respectively. The presence of LYG-202 resulted in decreasing capillary sprouting from the rat aorta rings, and the inhibitory activity was concentration-dependent.
LYG-202 inhibits angiogenesis in vivo
To determine whether anti-angiogenic effects of LYG-202 could be recapitulated in vivo, we extended our studies by the CAM model, which provides a unique model for investigating the effect of anti-angiogenic agents on the process of new blood vessel formation. As shown in Fig. 5 , there is a normal branching pattern of blood vessels formed after 2-day incubation in the control group, whereas LYG-202 blocked this angiogenesis. LYG-202 at 12 ng/egg incubation showed a notable restraint, whereas 60 ng/egg LYG-202 drastically impaired neovascularization of the CAM, accompanied by a lack of prominent vessel networks. Quantitative analysis revealed that LYG-202 at 2.4, 12, and 60 ng/ egg caused 12%, 39%, and 58% reduction in the number of new blood vessels, respectively. These results demonstrate that LYG-202 is able to suppress angiogenesis in CAM models. 
Influence of LYG-202 on VEGFR-2 and related signaling pathways
In this part of the study, we performed Western-blot analysis to evaluate the molecular mechanism by which LYG-202 antagonizes VEGF-stimulated angiogenesis in HUVECs. We investigated the effects of LYG-202 on the VEGF-induced activation of VEGFR-2 as well as the related downstream signaling molecules Akt, ERK1/2, and p38 MAPK. As shown in Fig. 6 , the protein expression level of the phosphorylated VEGFR-2 was apparently induced by the addition of exogenous VEGF to HUVECs. Pre-treatment with LYG-202 down-regulated the VEGF-induced phosphorylation of VEGFR-2 without affecting the overall protein levels. Treatment with LYG-202 efficiently inhibited phosphorylation of Akt, ERK1/2, and p38 MAPK activated by VEGF in a concentration-dependent manner. In all cases, the total steady state protein levels of Akt, ERK1/2, and p38 MAPK remained unchanged. Taken together, these results suggest that VEGFR-2 may be a responsible target of LYG-202 leading to interruption of VEGF-stimulated signal transduction. 6 . Effect of LYG-202 on VEGF-stimulated activation of VEGFR-2 and related signaling pathways. A) Western blot assays were used to examine the total and phosphorylated protein levels of VEGFR-2, Akt, ERK1/2, and p38 MAPK. B) Densitometric analysis gave the relative ratios of phosphorylated VEGFR-2 / total VEGFR-2, phosphorylated Akt / total Akt, phosphorylated ERK1/2 / total ERK1/2, and phosphorylated p38 MAPK / total p38 MAPK. Each reported value is a mean ± S.E.M. *P < 0.05, significantly different from the VEGF-treated group, for each LYG-202-treated group. LYG-202 Exhibits Antiangiogenic Activity Discussion Angiogenesis, the process leading to the formation of new blood vessels, contains multiplex steps (21) . The initial event begins when angiogenic cytokines are increased to break the balance with anti-angiogenic cytokines. The second phase occurs when activated endothelial cells start to proliferate and migrate towards the mitogenic stimulus where they form a vascular sprout. This phase also requires the release of proteolytic enzymes like MMPs, which degrade the basement membrane to facilitate the invasion of endothelial cells. In the third phase, the vascular sprout forms a lumen. Finally, pericytes are recruited to the area to provide further support for the new vessel. There are many molecules and cells involved in this process. Endothelial cell proliferation, migration, and anastomosis are the most important steps of this process (22) . One of the key mediators of angiogenesis is VEGF, which regulates most of the steps in angiogenic cascades (23) .
In this study, we used both in vitro and in vivo approaches to investigate the potential anti-angiogenic activity of LYG-202. LYG-202 inhibited the migration and capillary-like chords formation of HUVECs in response to VEGF stimulation in vitro, but it did not suppress their growth in the concentrations used in these experiments (data not shown). Furthermore, it suppressed the microvessel sprouting from vascular tissues of rat aorta. In addition, it significantly decreased new vessel formation and vascular network in the CAM model. These results implied that LYG-202 could act as a probable anti-angiogenic compound.
VEGF transduces signals mainly through three receptors, VEGFR-1, -2, and -3 (24) . VEGFR-1 seems to participate in pathological angiogenesis, but its function and signaling remain unclear (25, 26) . Nevertheless, VEGFR-3 is responsible for lymphangiogenesis (26) . Of these receptors, VEGFR-2 appears to play a critical role in the regulation of angiogenesis. It is a member of the receptor tyrosine kinase families, almost exclusively located on endothelial cells. Its expression levels are low in normal tissues and only increase in pathologic states when neovascularization occurs (27) . Binding of VEGF and VEGFR-2 induces receptor tyrosine phosphorylation and stimulates the phospholipase Cγ-protein kinase C-MAPK / ERK pathway (28), the stress-activated protein kinase 2 / p38 pathway (29) , as well as the phosphatidylinositol 3-kinase / AKT pathway (30) . Apart from this, VEGFR-2 can interact with other components like integrin α v β 3 to form a complex on endothelial cells, and this receptor cross-talk is able to initiate some pathological consequences and regulatory events (31). Ogawa et al showed that specific activation of VEGFR-2 with VEGF has demonstrated potent activity of endothelial cells in vitro and in vivo, strongly supporting the notion that activation of VEGFR-2 alone can efficiently stimulate angiogenesis (32) . Therefore VEGFR-2 is thought to be a major signaling component in angiogenesis.
Flavonoids have been reported to inhibit activations of several tyrosine and serine kinases (33), so we considered the kinase activities of VEGFR-2 and its downstream kinases as possible molecular targets of LYG-202. We observed that LYG-202 inhibited VEGFinduced phosphorylation of VEGFR-2 in HUVECs, but did not affect the levels of total VEGFR-2 proteins. This effect may explain the decreasing of VEGF-induced phosphorylation of Akt, ERK1/2, and p38 MAPK, the major downstream kinases of VEGFR-2.
As downstream signal molecules of VEGF, the protein kinase Akt exerts its functions to promote survival and increase permeability in endothelial cells by causing phosphorylation of endothelial nitric oxide synthase (eNOS) and elevating NO production (34); ERK activation is importantly involved in proliferation, migration, and morphogenesis of endothelial cells (35) ; Likewise, p38 MAPK also plays a key role in cell migration by enhancing vascular hyperpermeability (36) . Thus, suppression of these kinase activations has been related to inhibition of angiogenesis. It was observed that LYG-202 markedly interrupted the VEGF-induced phosphorylation of Akt, ERK1/2, and p38 MAPK, which indicated that the inhibitive effect on the responsibility of HUVECs activation. This inhibitory effect of LYG-202 on VEGFR-2 phosphorylation and its signal transduction may be at least in part contribute to its potent anti-angiogenic activity. To fully understand the mechanism, our further investigations will focus on the details molecules affected by LYG-202, which mediate the activation of these kinases, and the changes of their downstream targets.
Our study on the effect of LYG-202 is ongoing. Most flavonoids have poor water solubility, which may somewhat limit their practical pharmacological use in the clinic. However, LYG-202 has a piperazine substitution at the 7′-position that should increase the hydrophilicity of this new compound, which may possibly improve its water solubility by combining it with an acid like hydrochloric acid to form the salt. The better hydrophilicity may decrease the solubility restriction and improve its pharmaceutical properties. For further understand the features of this new compound, we will continue to investigate its characteristics and compare it with other flavonoids to analyze its special advantageous activities. In addition, our previous study found that that LYG-202 possessed antitumor effect both in vivo and in vitro (37) . Angiogenesis is essential for tumor growth (38) because it can deliver oxygen and nutrients and remove waste products of metabolism, two processes required for tumor growth and progression. Therefore whether LYG-202 can inhibit tumor angiogenesis still needs to be established in the future.
In summary, we provided evidence for the first time that LYG-202 has potent anti-angiogenic activity in vitro and in vivo. It exerted inhibition by interfering with angiogenesis at various steps and through interfering with VEGF signal transduction. However, the precise molecular mechanisms of this effect and its other activities remain unknown. Additional studies are now underway to further characterize this new compound.
